PRD Therapeutics

Executive Summary

PRD Therapeutics is a Japanese drug discovery startup pioneering first-in-class oral small molecule therapies targeting lipid metabolism disorders. The company's core platform focuses on selective inhibition of SOAT2 (acyl-coenzyme A:cholesterol acyltransferase 2), with its lead program PRD001 being the world's first and only selective SOAT2 inhibitor. PRD001 is initially being developed for homozygous familial hypercholesterolemia (HoFH), a rare and severe genetic dyslipidemia, with planned expansion into metabolic dysfunction-associated steatotic liver disease (MASH/MASLD) and common dyslipidemias. Founded in 2021 and based in Tokyo, the company has raised $10 million to advance its preclinical and early clinical pipeline, leveraging a novel mechanism that may offer improved efficacy and tolerability over existing therapies such as statins and PCSK9 inhibitors.

Upcoming Catalysts (preview)

• TBDInitiation of Phase 1/2 clinical trial for PRD001 in HoFH80% success
• TBDPresentation of preclinical data for PRD001 in MASH/MASLD models at a medical conference90% success
• TBDOrphan Drug Designation or Fast Track status from regulatory authorities for PRD00170% success